

## Letter to the Editor

# Type C Mucosa in Pouch Surveillance: How Real is the Risk?

Maarten te Groen<sup>\*</sup>, Frank Hoentjen, Lauranne Derikx

Radboud University Medical Centre, Nijmegen, The Netherlands

Corresponding author: Maarten te Groen, MD, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands. Tel. +31 (0)24 361 1111; Email: [maarten.tegroen@radboudumc.nl](mailto:maarten.tegroen@radboudumc.nl)



Reply to:

Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. Samaan *et al.* *Journal of Crohn's and Colitis* 2019;13(6):735–43.

Dear Editors,

We read with great interest the article by Samaan *et al.*, reporting on pouch surveillance in a large cohort of inflammatory bowel disease [IBD] patients. Their primary findings were a wide variation in surveillance practice, with a relatively high rate of colorectal neoplasia development in low-risk patients. Therefore, the authors advocate for uniform pouch surveillance recommendations. We confirm the wide variety in pouch surveillance in our own cohort [27.4% >1 pouchoscopy/3 years, 21% <1 pouchoscopy/10 years] and endorse the need for uniform surveillance guidelines.<sup>1</sup>

Two low-risk patients out of 272 IBD patients with ileal pouch-anal anastomosis [IPAA] [0.7%] developed a pouch carcinoma in their cohort. Therefore, the authors recommend a more intensive pouch surveillance strategy in low-risk patients compared to current guidelines. They suggest a pouchoscopy 1 year after IPAA construction in order to stratify patients based upon the presence of type C pouch mucosa, characterized by persistent atrophy and inflammation.<sup>2</sup> A type C mucosa might be predictive for subsequent development of pouch neoplasia. However, we question the use of type C mucosa for risk stratification due to the following concerns.

First, there is no clear histological definition of type C mucosa. Villous surface density is used for grading, but quantitative cut-offs are not described.<sup>2</sup> The assessment of type C mucosa is not part of routine histological evaluation in most centres, and limits the implementation of this factor in daily practice. In addition, the evidence for type C mucosa as a high-risk feature for pouch neoplasia is based on a few now dated studies that reported conflicting results.<sup>2–4</sup> The reported neoplasia risk for type C mucosa varied between 0% and 71% in these studies.

Second, type C mucosa is frequently accompanied by severe pouch inflammation. It is thought that chronic pouch inflammation results in mucosal atrophy with subsequent malignant transformation.<sup>3</sup> However, in the two largest cohort studies to date [ $n = 1200$  and  $n = 3203$  patients], pouchitis was not identified as a risk factor for pouch neoplasia.<sup>1</sup>

Third, it is not clear in which time frame type C mucosa develops. As such, one may develop type C mucosa after the first pouchoscopy 1 year following IPAA construction. On the other hand, most patients with

severe pouch atrophy immediately after ileostomy loop closure showed [partial] regression of the atrophic mucosa after 3 years of follow up.<sup>2</sup>

In conclusion, we confirm a wide variety in pouch surveillance as seen by the authors, emphasizing the pressing need for optimization and standardization of pouch surveillance practices. However, we advocate a different strategy as previously discussed, without stratification based on type C mucosa.<sup>5</sup>

## Funding

No specific funding was received for this work.

## Conflict of Interest

The authors state no conflicts of interest.

## Acknowledgments

No writing assistance was used for this work. The manuscript, including related data, has not been previously published and the manuscript is not under consideration elsewhere.

## Author contributions

M.G.: letter design and drafting of the manuscript, final approval of the submitted version; F.H., L.D.: letter design and critical revision of the manuscript, final approval of the submitted version.

## References

1. Derikx LA, Kievit W, Drenth JP, *et al.* Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. *Gastroenterology* 2014;146:119–28.e1.
2. Veress B, Reinholt FP, Lindquist K, Löfberg R, Liljeqvist L. Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. *Gastroenterology* 1995;109:1090–7.
3. Gullberg K, Ståhlberg D, Liljeqvist L, *et al.* Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. *Gastroenterology* 1997;112:1487–92.
4. Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. *Gastroenterology* 2001;121:275–81.
5. Derikx LA, Nissen LH, Oldenburg B, Hoentjen F. Controversies in pouch surveillance for patients with inflammatory bowel disease. *J Crohns Colitis* 2016;10:747–51.